Accordingly, it has been recently shown that the TP53 apoptotic network, and in particular inactivation of TP53, BAX, and PMAIP1, mediates resistance to BCL2 inhibition in AML [58]. This evidence concerns the gene BCL2 and acute myeloid leukemia.